FDA approves GSK’s drug Horizant for a new cure

Horizant, a medication which was already approved for treatment of restless legs syndrome (RLS) is recently been approved by the FDA (Food and Drug Administration) to be used as a therapeutic remedial approach for curing the nerve pain associated with shingles. The drug is the baby of XenoPort Inc and GlaxoSmithKline Plc drug manufacturers, but currently the two pharma companies, who are partners, are undergoing a legal fight as it has been alleged by XenoPort that GSK has breached with the contract. The approval of the drug for treatment of post-herpetic neuralgia (PHN) in young individuals is proved to of great significance as around 1 million individuals in the U.S have been found to get afflicted from shingles every year. Of the total individuals affected from this detrimental condition, approximately 10 % of the patients were found to develop this detrimental health condition called PHN. This catastrophic condition results from the curing of the infection caused by the outbreak of the virus herpes zoster, which is known commonly as shingles. The controlled clinical trial study of the drug Horizant to find the effectiveness and potency of the drug for healing of post-herpetic neuralgia was carried out for a period of 12 weeks. The common but mild side effects that were observed in PHN suffering patients, who underwent the treatment, include dizziness and drowsiness. Michael Yee, RBC Capital analyst said that despite the fact that XenoPort shares have seen a downfall following the dispute of contract with GSK, it is reported that XenoPort will be getting a high point payment of around $10 million from its partner once, the first set of sales of the medication is done. Acedrugstore 3rd Street, Bakersfield, CA, USA 93311 16471051516 http://www.acedrugstore.com/ http://www.acedrugstore.com/kamagra-jelly.html

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.